{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:38:41Z","timestamp":1791236321494,"version":"4.1.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cannabis Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Changing trends in legal recreational cannabis markets necessitates the continuous monitoring of important market metrics such as price, potency, type, and availability of cannabis products which may influence consumer purchasing behavior. After initial legalization of recreational cannabis use in Canada in 2018 and expansion of the legal market in 2019, an increase in product types and decrease in prices were observed. The purpose of the present study was to provide an update on products on offer to cannabis consumers in Ontario, the largest Cannabis market in Canada, five years after initial federal legalization of non-medical cannabis use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Data were obtained from the Ontario Cannabis Store (OCS) Website, the sole wholesaler and online market in Ontario between January and April 2024. Information on product type, prices, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) potency and plant type was extracted and products were grouped by OCS categories and sub-categories, and by route of administration (Inhaled, ingestible, topical and others).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 1727 products were mapped, of which the majority available were inhaled products, sub-divided into smoking, vaping or concentrates (n\u2009=\u20091271). The majority of inhaled products were predominantly indica-dominant while most ingestible products (e.g. edibles) were mainly sativa-dominant. Most inhaled products were \u201cvery strong products\u201d, i.e., THC potency of 20% or greater (greater than 97%, 96% and 99% of all dried flower, vaping and concentrate products, respectively). All edibles were within the legally acceptable limit of 10\u00a0mg of THC per container. Average prices were lowest for dried flower products ($7.91\/g) among inhaled products (pre-rolls: $9.65\/g, 510 thread cartridges: $37.7\/g, infused flower: $18.66\/g). Compared to our previous study in 2022, which utilized data from the same website and similar extraction methods, the total number of products on the legal market declined, while the number of edible products (particularly gummies) and disposable vapes, increased. Prices of all flower products (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), most abundant vapes (disposable vapes and thread cartridges:\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and soft chews (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.027) decreased in 2024 compared to 2022 at the 5% significance level. Conversely, THC potencies of products available generally increased (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Given the trend of decreasing price and changes in products available, continuous monitoring of the cannabis market is vital. This is necessary to assess the consequences of legalization and inform legal amendments such as price control and potency limits that may curb potential negative consequences possible with the current market trend.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42238-026-00444-6","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:16:02Z","timestamp":1778112962000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["An update on cannabis products, cannabinoid content, plant type, and prices five years after legalization in Ontario, Canada"],"prefix":"10.1186","volume":"8","author":[{"given":"Paulina","family":"Antwi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Matheson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lohith","family":"Balaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Wickens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Le Foll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Rueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Di Ciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"444_CR1","unstructured":"Alcohol and Gaming Commission of Ontario. Status of current Cannabis Retail Store Applications. 2025. August 6, 2025; Available from: https:\/\/www.agco.ca\/en\/cannabis\/status-current-cannabis-retail-store-applications."},{"issue":"4","key":"444_CR2","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3109\/16066359.2016.1139699","volume":"24","author":"C Ben Lakhdar","year":"2016","unstructured":"Ben Lakhdar C, Vaillant NG, Wolff F-C. Price elasticity of demand for cannabis: does potency matter? Addict Res Theory. 2016;24(4):300\u201312.","journal-title":"Addict Res Theory"},{"key":"444_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ypmed.2017.06.034","volume":"104","author":"AJ Budney","year":"2017","unstructured":"Budney AJ, Borodovsky JT. The potential impact of cannabis legalization on the development of cannabis use disorders. Prev Med. 2017;104:31\u20136.","journal-title":"Prev Med"},{"key":"444_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.109892","volume":"258","author":"RC Callaghan","year":"2024","unstructured":"Callaghan RC, et al. Canada\u2019s cannabis legalization and police-reported cannabis-related criminal incidents among youth, 2015\u20132021. Drug Alcohol Depend. 2024;258:109892.","journal-title":"Drug Alcohol Depend"},{"key":"444_CR5","unstructured":"Cannabis Act, G.o. Canada, Editor. 2018."},{"key":"444_CR6","unstructured":"Center for Addiction and Mental Health. Cannabis Policy Framework. 2014."},{"issue":"12","key":"444_CR7","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1038\/s41386-025-02175-3","volume":"50","author":"E Chesney","year":"2025","unstructured":"Chesney E, et al. Does cannabidiol reduce the adverse effects of cannabis in schizophrenia? A randomised, double-blind, cross-over trial. Neuropsychopharmacology. 2025;50(12):1759\u201367.","journal-title":"Neuropsychopharmacology"},{"key":"444_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2021.108610","volume":"193","author":"V Chiu","year":"2021","unstructured":"Chiu V, et al. Public health impacts to date of the legalisation of medical and recreational cannabis use in the USA. Neuropharmacology. 2021;193:108610.","journal-title":"Neuropharmacology"},{"key":"444_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2025.104917","volume":"143","author":"P Di Ciano","year":"2025","unstructured":"Di Ciano P, Wickens CM, Le Foll B. Cannabis legalization in Canada: implications for research. Int J Drug Policy. 2025;143:104917.","journal-title":"Int J Drug Policy"},{"issue":"8","key":"444_CR10","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.clinthera.2023.06.015","volume":"45","author":"JA Dilley","year":"2023","unstructured":"Dilley JA, et al. Cannabis retail market indicators in five legal states in the United States: a public health perspective. Clin Ther. 2023;45(8):778\u201386.","journal-title":"Clin Ther"},{"issue":"8","key":"444_CR11","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1007\/s43678-024-00736-x","volume":"26","author":"PM Dion","year":"2024","unstructured":"Dion PM, et al. Road hazard: a systematic review of traffic injuries following recreational cannabis legalization. CJEM. 2024;26(8):554\u201363.","journal-title":"CJEM"},{"key":"444_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2025.104838","volume":"142","author":"T Dodd","year":"2025","unstructured":"Dodd T, Colistro T, Maillet MA. Price elasticity of demand for cannabis: post-legalization estimates of the regulated cannabis market in British Columbia, Canada. Int J Drug Policy. 2025;142:104838.","journal-title":"Int J Drug Policy"},{"issue":"5","key":"444_CR13","doi-asserted-by":"publisher","first-page":"744","DOI":"10.15288\/jsad.22-00269","volume":"84","author":"JR Donnan","year":"2023","unstructured":"Donnan JR, et al. Drivers of purchase decisions among consumers of dried flower cannabis products: a discrete choice experiment. J Stud Alcohol Drugs. 2023;84(5):744\u201353.","journal-title":"J Stud Alcohol Drugs"},{"key":"444_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104644","volume":"134","author":"JR Donnan","year":"2024","unstructured":"Donnan JR, et al. Bridging the gap: exploring consumer experiences and motivations for transitioning between illicit and regulated cannabis markets. Int J Drug Policy. 2024;134:104644.","journal-title":"Int J Drug Policy"},{"issue":"5","key":"444_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0292336","volume":"19","author":"J Donnan","year":"2024","unstructured":"Donnan J, et al. Exploring consumer preferences for cannabis edible products to support public health policy: a discrete choice experiment. PLoS ONE. 2024;19(5):e0292336.","journal-title":"PLoS ONE"},{"issue":"6","key":"444_CR16","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/s41386-022-01478-z","volume":"48","author":"A Englund","year":"2023","unstructured":"Englund A, et al. Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios. Neuropsychopharmacology. 2023;48(6):869\u201376.","journal-title":"Neuropsychopharmacology"},{"key":"444_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2019.102611","volume":"75","author":"CL Firth","year":"2020","unstructured":"Firth CL, et al. How high: differences in the developments of cannabis markets in two legalized states. Int J Drug Policy. 2020;75:102611.","journal-title":"Int J Drug Policy"},{"key":"444_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103381","volume":"99","author":"B Fischer","year":"2022","unstructured":"Fischer B, et al. Lower-risk cannabis use guidelines (LRCUG) for reducing health harms from non-medical cannabis use: a comprehensive evidence and recommendations update. Int J Drug Policy. 2022;99:103381.","journal-title":"Int J Drug Policy"},{"issue":"39","key":"444_CR19","doi-asserted-by":"publisher","first-page":"E1351","DOI":"10.1503\/cmaj.230808","volume":"195","author":"B Fischer","year":"2023","unstructured":"Fischer B, Jutras-Aswad D, Hall W. Outcomes associated with nonmedical cannabis legalization policy in Canada: taking stock at the 5-year mark. CMAJ. 2023;195(39):E1351\u20133.","journal-title":"CMAJ"},{"key":"444_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.829944","volume":"13","author":"D Fortin","year":"2022","unstructured":"Fortin D, et al. A \u201cGood\u201d Smoke? The off-label use of cannabidiol to reduce cannabis use. Front Psychiatry. 2022;13:829944.","journal-title":"Front Psychiatry"},{"issue":"15","key":"444_CR21","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1017\/S0033291715001178","volume":"45","author":"TP Freeman","year":"2015","unstructured":"Freeman TP, Winstock AR. Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. Psychol Med. 2015;45(15):3181\u20139.","journal-title":"Psychol Med"},{"issue":"6","key":"444_CR22","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1111\/add.14525","volume":"114","author":"TP Freeman","year":"2019","unstructured":"Freeman TP, et al. Increasing potency and price of cannabis in Europe, 2006\u201316. Addiction. 2019;114(6):1015\u201323.","journal-title":"Addiction"},{"key":"444_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2019.102658","volume":"76","author":"S Goodman","year":"2020","unstructured":"Goodman S, et al. Prevalence and forms of cannabis use in legal vs. illegal recreational cannabis markets. Int J Drug Policy. 2020;76:102658.","journal-title":"Int J Drug Policy"},{"issue":"3","key":"444_CR24","doi-asserted-by":"publisher","first-page":"392","DOI":"10.15288\/jsad.2022.83.392","volume":"83","author":"S Goodman","year":"2022","unstructured":"Goodman S, Wadsworth E, Hammond D. Reasons for purchasing cannabis from illegal sources in legal markets: findings among cannabis consumers in Canada and U.S. states, 2019-2020. J Stud Alcohol Drugs. 2022;83(3):392\u2013401.","journal-title":"J Stud Alcohol Drugs"},{"key":"444_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104385","volume":"127","author":"S Goodman","year":"2024","unstructured":"Goodman S, et al. How have cannabis use and related indicators changed since legalization of cannabis for non-medical purposes? Results of the Canadian Cannabis Survey 2018\u20132022. Int J Drug Policy. 2024;127:104385.","journal-title":"Int J Drug Policy"},{"key":"444_CR26","unstructured":"Government of Canada. Regulations Amending the Cannabis Regulations (New Classes of Cannabis): SOR\/2019\u2013206. 2019; Part II, Volume 153, Number 13. Available from: https:\/\/gazette.gc.ca\/rp-pr\/p2\/2019\/2019-06-26\/html\/sor-dors206-eng.html."},{"issue":"2","key":"444_CR27","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/wps.20735","volume":"19","author":"W Hall","year":"2020","unstructured":"Hall W, Lynskey M. Assessing the public health impacts of legalizing recreational cannabis use: the US experience. World Psychiatry. 2020;19(2):179\u201386.","journal-title":"World Psychiatry"},{"key":"444_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102698","volume":"77","author":"D Hammond","year":"2020","unstructured":"Hammond D, et al. Evaluating the impacts of cannabis legalization: The International Cannabis Policy Study. Int J Drug Policy. 2020;77:102698.","journal-title":"Int J Drug Policy"},{"key":"444_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103716","volume":"105","author":"D Hammond","year":"2022","unstructured":"Hammond D, et al. Trends in the use of cannabis products in Canada and the USA, 2018\u20132020: findings from the International Cannabis Policy Study. Int J Drug Policy. 2022;105:103716.","journal-title":"Int J Drug Policy"},{"key":"444_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2025.108336","volume":"198","author":"B Han","year":"2025","unstructured":"Han B, Shi Y. A content analysis of cannabis edible product characteristics, packaging features, and online promotions. Prev Med. 2025;198:108336.","journal-title":"Prev Med"},{"issue":"3","key":"444_CR31","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1089\/can.2024.0164","volume":"10","author":"B Han","year":"2025","unstructured":"Han B, et al. Estimating the price elasticity of cannabis use among U.S. adults: evidence from states with recreational cannabis commercialization. Cannabis Cannabinoid Res. 2025;10(3):480\u20138.","journal-title":"Cannabis Cannabinoid Res"},{"key":"444_CR32","unstructured":"Health Canada. Canadian Cannabis Survey 2018 Summary. 2018."},{"key":"444_CR33","unstructured":"Health Canada. Key Findings. Cannabis use (non-medical) in Canada. 2024, canada.ca."},{"key":"444_CR34","unstructured":"Health Canada. Canadian Cannabis Survey 2024: Summary. 2024, canada.ca."},{"issue":"9929","key":"444_CR35","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(13)62417-4","volume":"383","author":"J Holmes","year":"2014","unstructured":"Holmes J, et al. Effects of minimum unit pricing for alcohol on different income and socioeconomic groups: a modelling study. Lancet. 2014;383(9929):1655\u201364.","journal-title":"Lancet"},{"key":"444_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.111060","volume":"255","author":"S Imtiaz","year":"2024","unstructured":"Imtiaz S, et al. Cannabis legalization and driving under the influence of cannabis and driving under the influence of alcohol among adult and adolescent drivers in Ontario, Canada (2001\u20132019). Drug Alcohol Depend. 2024;255:111060.","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"444_CR37","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.clinthera.2023.03.005","volume":"45","author":"B Kilmer","year":"2023","unstructured":"Kilmer B, Perez-Davila S. Nine insights from 10 years of legal cannabis for nonmedical purposes. Clin Ther. 2023;45(6):496\u2013505.","journal-title":"Clin Ther"},{"issue":"7","key":"444_CR38","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1176\/appi.ajp.20240269","volume":"182","author":"S Lake","year":"2025","unstructured":"Lake S, et al. High-potency cannabis use and health: a systematic review of observational and experimental studies. Am J Psychiatry. 2025;182(7):616\u201338.","journal-title":"Am J Psychiatry"},{"issue":"04","key":"444_CR39","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1055\/s-0043-122240","volume":"84","author":"MA Lewis","year":"2018","unstructured":"Lewis MA, Russo EB, Smith KM. Pharmacological foundations of cannabis chemovars. Planta Med. 2018;84(04):225\u201333.","journal-title":"Planta Med"},{"issue":"4","key":"444_CR40","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/dar.13069","volume":"39","author":"S Mahamad","year":"2020","unstructured":"Mahamad S, et al. Availability, retail price and potency of legal and illegal cannabis in Canada after recreational cannabis legalisation. Drug Alcohol Rev. 2020;39(4):337\u201346.","journal-title":"Drug Alcohol Rev"},{"key":"444_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104039","volume":"116","author":"J Manthey","year":"2023","unstructured":"Manthey J, et al. The impact of legal cannabis availability on cannabis use and health outcomes: a systematic review. Int J Drug Policy. 2023;116:104039.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"444_CR42","first-page":"50","volume":"8","author":"S Marinello","year":"2025","unstructured":"Marinello S. The impact of recreational cannabis markets on cannabis use among adolescents and adults: a synthetic control analysis. Cannabis Basel. 2025;8(1):50\u201364.","journal-title":"Cannabis Basel"},{"key":"444_CR43","doi-asserted-by":"publisher","first-page":"192","DOI":"10.4337\/9781035329397.00022","volume-title":"Intellectual property and cannabis","author":"M Marzetti","year":"2025","unstructured":"Marzetti M. Cannabis regulation and IP rights in Uruguay. In: Intellectual property and cannabis. Edward Elgar Publishing; 2025. p. 192\u2013210."},{"key":"444_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.591979","volume":"11","author":"J Matheson","year":"2020","unstructured":"Matheson J, Le Foll B. Cannabis legalization and acute harm from high potency cannabis products: a narrative review and recommendations for public health. Front Psychiatry. 2020;11:591979.","journal-title":"Front Psychiatry"},{"key":"444_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2025.104793","volume":"139","author":"AJ McDonald","year":"2025","unstructured":"McDonald AJ, et al. Association of recreational cannabis legalization with changes in medical, illegal, and total cannabis expenditures in Canada. Int J Drug Policy. 2025;139:104793.","journal-title":"Int J Drug Policy"},{"issue":"8","key":"444_CR46","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1001\/jamapsychiatry.2020.0339","volume":"77","author":"RM Murray","year":"2020","unstructured":"Murray RM, Hall W. Will legalization and commercialization of cannabis use increase the incidence and prevalence of psychosis? JAMA Psychiat. 2020;77(8):777\u20138.","journal-title":"JAMA Psychiat"},{"issue":"5","key":"444_CR47","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1111\/dar.13650","volume":"42","author":"DT Myran","year":"2023","unstructured":"Myran DT, et al. Access to legal cannabis market in Canada over the four years following non-medical cannabis legalisation. Drug Alcohol Rev. 2023;42(5):1114\u20139.","journal-title":"Drug Alcohol Rev"},{"key":"444_CR48","doi-asserted-by":"crossref","unstructured":"Navarrete, F., et al., Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders. Frontiers in Pharmacology, 2021. Volume 12 - 2021.","DOI":"10.3389\/fphar.2021.626010"},{"issue":"5","key":"444_CR49","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1089\/can.2022.0213","volume":"8","author":"SA Okey","year":"2023","unstructured":"Okey SA, et al. An ecological examination of indica versus sativa and primary terpenes on the subjective effects of smoked cannabis: a preliminary investigation. Cannabis Cannabinoid Res. 2023;8(5):857\u201366.","journal-title":"Cannabis Cannabinoid Res"},{"key":"444_CR50","unstructured":"Okey, S.A., et al., What Influences Cannabis Purchasing Decisions? Perspectives from Cannabis Retail Employees and Customers in Washington State. Cannabis Cannabinoid Res, 2025."},{"key":"444_CR51","unstructured":"Ontario Cannabis Store. Cannabis Basics. What is THC? 2022. Aug 27, 2025. Available from: https:\/\/ocs.ca\/blogs\/cannabis-basics\/what-is-thc."},{"key":"444_CR52","unstructured":"Ontario Cannabis Store. Ontario Cannabis Marketplace: By the Numbers (Jan. 1\u2013Dec. 31, 2024). 2025."},{"key":"444_CR53","unstructured":"Ontario Cannabis Store. 2025 August 27, 2025]; Available from: https:\/\/ocs.ca\/."},{"key":"444_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2022.107360","volume":"132","author":"V Paulus","year":"2022","unstructured":"Paulus V, et al. Cannabidiol in the context of substance use disorder treatment: a systematic review. Addict Behav. 2022;132:107360.","journal-title":"Addict Behav"},{"issue":"10","key":"444_CR55","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1089\/acm.2013.0190","volume":"20","author":"DD Pearce","year":"2014","unstructured":"Pearce DD, Mitsouras K, Irizarry KJ. Discriminating the effects of Cannabis sativa and Cannabis indica: a web survey of medical cannabis users. J Altern Complement Med. 2014;20(10):787\u201391.","journal-title":"J Altern Complement Med"},{"key":"444_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.921493","volume":"13","author":"SD Pennypacker","year":"2022","unstructured":"Pennypacker SD, et al. Potency and therapeutic THC and CBD ratios: U.S. cannabis markets overshoot. Front Pharmacol. 2022;13:921493.","journal-title":"Front Pharmacol"},{"issue":"9","key":"444_CR57","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/S2215-0366(22)00161-4","volume":"9","author":"K Petrilli","year":"2022","unstructured":"Petrilli K, et al. Association of cannabis potency with mental ill health and addiction: a systematic review. Lancet Psychiatry. 2022;9(9):736\u201350.","journal-title":"Lancet Psychiatry"},{"key":"444_CR58","doi-asserted-by":"crossref","unstructured":"Queirolo R, \u00c1lvarez E, Sotto B. Cannabis in Uruguay, in Oxford Research Encyclopedia of Latin American History. 2024.","DOI":"10.1093\/acrefore\/9780199366439.013.1101"},{"issue":"4","key":"444_CR59","first-page":"3","volume":"32","author":"M Rotermann","year":"2021","unstructured":"Rotermann M. Looking back from 2020, how cannabis use and related behaviours changed in Canada. Health Rep. 2021;32(4):3\u201314.","journal-title":"Health Rep"},{"key":"444_CR60","doi-asserted-by":"crossref","unstructured":"Rubin-Kahana DS, et al., The impact of cannabis legalization for recreational purposes on youth: A narrative review of the Canadian experience. Frontiers in Psychiatry, 2022. Volume 13 - 2022.","DOI":"10.3389\/fpsyt.2022.984485"},{"key":"444_CR61","doi-asserted-by":"publisher","DOI":"10.1111\/dar.70009","author":"S Rundle","year":"2025","unstructured":"Rundle S, et al. Self-reported cannabis prices and expenditures from legal and illegal sources five years after legalisation of non-medical cannabis in Canada. Drug Alcohol Rev. 2025. https:\/\/doi.org\/10.1111\/dar.70009.","journal-title":"Drug Alcohol Rev"},{"key":"444_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugpo.2019.07.037","volume":"74","author":"Y Shi","year":"2019","unstructured":"Shi Y, et al. The impacts of potency, warning messages, and price on preferences for cannabis flower products. Int J Drug Policy. 2019;74:1\u201310.","journal-title":"Int J Drug Policy"},{"issue":"5","key":"444_CR63","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1037\/pha0000462","volume":"30","author":"DJ Sholler","year":"2022","unstructured":"Sholler DJ, et al. Use patterns, beliefs, experiences, and behavioral economic demand of indica and sativa cannabis: a cross-sectional survey of cannabis users. Exp Clin Psychopharmacol. 2022;30(5):575\u201383.","journal-title":"Exp Clin Psychopharmacol"},{"issue":"12","key":"444_CR64","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1111\/add.13886","volume":"112","author":"R Smart","year":"2017","unstructured":"Smart R, et al. Variation in cannabis potency and prices in a newly legal market: evidence from 30 million cannabis sales in Washington state. Addiction. 2017;112(12):2167\u201377.","journal-title":"Addiction"},{"issue":"5","key":"444_CR65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0267498","volume":"17","author":"CJ Smith","year":"2022","unstructured":"Smith CJ, et al. The phytochemical diversity of commercial cannabis in the United States. PLoS ONE. 2022;17(5):e0267498.","journal-title":"PLoS ONE"},{"issue":"1","key":"444_CR66","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1038\/s41598-019-39462-1","volume":"9","author":"SS Stith","year":"2019","unstructured":"Stith SS, et al. The association between cannabis product characteristics and symptom relief. Sci Rep. 2019;9(1):2712.","journal-title":"Sci Rep"},{"key":"444_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1111330","volume":"14","author":"F Tassone","year":"2023","unstructured":"Tassone F, et al. On offer to Ontario consumers three years after legalization: a profile of cannabis products, cannabinoid content, plant type, and prices. Front Psychiatry. 2023;14:1111330.","journal-title":"Front Psychiatry"},{"issue":"1","key":"444_CR68","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12954-023-00753-6","volume":"20","author":"E Wadsworth","year":"2023","unstructured":"Wadsworth E, et al. Legal sourcing of ten cannabis products in the Canadian cannabis market, 2019\u20132021: a repeat cross-sectional study. Harm Reduct J. 2023;20(1):19.","journal-title":"Harm Reduct J"},{"issue":"2","key":"444_CR69","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/j.1360-0443.2008.02438.x","volume":"104","author":"AC Wagenaar","year":"2009","unstructured":"Wagenaar AC, Salois MJ, Komro KA. Effects of beverage alcohol price and tax levels on drinking: a meta-analysis of 1003 estimates from 112 studies. Addiction. 2009;104(2):179\u201390.","journal-title":"Addiction"}],"container-title":["Journal of Cannabis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42238-026-00444-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42238-026-00444-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42238-026-00444-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T05:40:56Z","timestamp":1782884456000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s42238-026-00444-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["444"],"URL":"https:\/\/doi.org\/10.1186\/s42238-026-00444-6","relation":{},"ISSN":["2522-5782"],"issn-type":[{"value":"2522-5782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"25 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Dr. Bernard Le Foll has obtained funding from Indivior for a clinical trial sponsored by Indivior. Dr. Le Foll has in-kind donations of placebo edibles from Indiva. Dr. Le Foll has obtained industry funding from Canopy Growth Corporation (through research grants handled by the Centre for Addiction and Mental Health and the University of Toronto). He has participated in a session of a National Advisory Board Meeting (Emerging Trends BUP-XR) for Indivior Canada and is part of Steering Board for a clinical trial for Indivior. He has been consultant for Shinogi, ThirdBridge and Changemark. He is part of a scientific advisory board for NFL Biosciences. He got travel support to attend an event by Bioprojet. He is supported by CAMH, Waypoint Centre for Mental Health Care, a clinician-scientist award from the department of Family and Community Medicine of the University of Toronto and a Chair in Addiction Psychiatry from the department of Psychiatry of University of Toronto. Dr. Christine Wickens serves on the Executive Committee of the International Council on Alcohol, Drugs and Traffic Safety (ICADTS) and on the Canadian Society of Forensic Science\u2019s Drugs and Driving Committee, which acts as an advisory body to the Department of Justice with respect to issues of drug impaired driving. She also served on the Board of Directors of the Canadian Association of Road Safety Professionals (CARSP). No other authors have any conflicts to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"77"}}